JAK抑制剂培非替尼的合成及合成工艺优化研究

珊 刘
{"title":"JAK抑制剂培非替尼的合成及合成工艺优化研究","authors":"珊 刘","doi":"10.12677/hjmce.2022.102016","DOIUrl":null,"url":null,"abstract":"Peficitinib is a novel Janus kinase 1 and Janus kinase 3 inhibitor developed by Astellas, a Japa-nese company. Peficitinib mainly treats the moderate or severe rheumatoid arthritis with in-刘珊 adequate response to methotrexate. At present, there are very few papers on the synthesis route of Peficitinib. In this paper, a complete synthesis route is designed, and then each step of the reaction is studied and optimized. Starting from 7-azindole, the target compound was obtained through seven steps including halogenation, substitution (upper protection), esterification, de-protection, ester hydrolysis, amidation and then substitution. By providing catalyst or changing other reaction conditions such as solvent, temperature and molar ratio of reactants, a reasona-ble route, high yield, short time and simple operation of Peficitinib synthesis process was suc-cessfully obtained, and the synthesis of Peficitinib can reach industrial production. The struc-tures of the target compounds and intermediates were confirmed by 1 H NMR, and the total yield of the route was 32.8%.","PeriodicalId":64647,"journal":{"name":"药物化学","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Study on Synthesis and Optimization of Syn-thesis Technology of JAK Inhibitor Peficitinib\",\"authors\":\"珊 刘\",\"doi\":\"10.12677/hjmce.2022.102016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Peficitinib is a novel Janus kinase 1 and Janus kinase 3 inhibitor developed by Astellas, a Japa-nese company. Peficitinib mainly treats the moderate or severe rheumatoid arthritis with in-刘珊 adequate response to methotrexate. At present, there are very few papers on the synthesis route of Peficitinib. In this paper, a complete synthesis route is designed, and then each step of the reaction is studied and optimized. Starting from 7-azindole, the target compound was obtained through seven steps including halogenation, substitution (upper protection), esterification, de-protection, ester hydrolysis, amidation and then substitution. By providing catalyst or changing other reaction conditions such as solvent, temperature and molar ratio of reactants, a reasona-ble route, high yield, short time and simple operation of Peficitinib synthesis process was suc-cessfully obtained, and the synthesis of Peficitinib can reach industrial production. The struc-tures of the target compounds and intermediates were confirmed by 1 H NMR, and the total yield of the route was 32.8%.\",\"PeriodicalId\":64647,\"journal\":{\"name\":\"药物化学\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"药物化学\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.12677/hjmce.2022.102016\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"药物化学","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.12677/hjmce.2022.102016","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

Peficitinib是日本安斯泰来公司开发的一种新型Janus激酶1和Janus激酶3抑制剂。培非替尼主要治疗甲氨蝶呤反应不充分的中重度类风湿性关节炎。目前,关于非西替尼合成路线的论文很少。本文设计了完整的合成路线,并对反应的各个步骤进行了研究和优化。从7-氮唑开始,经过卤化、取代(上部保护)、酯化、去保护、酯水解、酰胺化、取代等7个步骤得到目标化合物。通过提供催化剂或改变溶剂、温度、反应物的摩尔比等其他反应条件,成功地获得了路线合理、收率高、时间短、操作简单的贝非西替尼合成工艺,使合成的贝非西替尼达到工业化生产。目的化合物和中间体的结构经1h NMR确证,该路线的总产率为32.8%。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Study on Synthesis and Optimization of Syn-thesis Technology of JAK Inhibitor Peficitinib
Peficitinib is a novel Janus kinase 1 and Janus kinase 3 inhibitor developed by Astellas, a Japa-nese company. Peficitinib mainly treats the moderate or severe rheumatoid arthritis with in-刘珊 adequate response to methotrexate. At present, there are very few papers on the synthesis route of Peficitinib. In this paper, a complete synthesis route is designed, and then each step of the reaction is studied and optimized. Starting from 7-azindole, the target compound was obtained through seven steps including halogenation, substitution (upper protection), esterification, de-protection, ester hydrolysis, amidation and then substitution. By providing catalyst or changing other reaction conditions such as solvent, temperature and molar ratio of reactants, a reasona-ble route, high yield, short time and simple operation of Peficitinib synthesis process was suc-cessfully obtained, and the synthesis of Peficitinib can reach industrial production. The struc-tures of the target compounds and intermediates were confirmed by 1 H NMR, and the total yield of the route was 32.8%.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
23
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信